IL6 and head and neck squamous cell carcinoma: Interestingly, authors found a significant clinical improvement, in terms of increased overall survival and better response (Table 2), in patients with low IL-6 serum levels so that it could be considered a clinical predictive biomarker for response to cetuximab and dasatinib combined therapy in HNSCC patients.